{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:06:14Z","timestamp":1793300774802,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Penetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood\u2013brain barrier, which is the most impermeable. However, inflammation may lead to structural alterations of these barriers, modifying their permeability. The impact of blood\u2013brain barrier disruption on linezolid and tedizolid (antibiotics that may be alternatives to treat nosocomial meningitis) penetration in cerebrospinal fluid (CSF) remains unknown. The aim of this study is to evaluate the impact of blood brain barrier disruption on CSF penetration of linezolid and tedizolid. Female C57BI\/6\u2009J mice were used. Blood\u2013brain barrier disruption was induced by an intraperitoneal administration of lipopolysaccharide. Linezolid (40\u2009mg\/kg) or tedizolid\u2010phosphate (20\u2009mg\/kg) were injected intraperitoneally. All the plasma and CSF samples were analyzed with a validated UPLC\u2010MS\/MS method. Pharmacokinetic parameters were calculated using a non\u2010compartmental approach based on the free drug concentration. The penetration ratio from the plasma into the CSF was calculated by the AUC\n                    <jats:sub>0\u20108h<\/jats:sub>\n                    (Area Under Curve) ratio (AUC\n                    <jats:sub>0\u20108hCSF<\/jats:sub>\n                    \/AUC\n                    <jats:sub>0\u20108hplasma<\/jats:sub>\n                    ). Linezolid penetration ratio was 46.5% in control group and 46.1% in lipopolysaccharide group. Concerning tedizolid, penetration ratio was 5.5% in control group and 15.5% in lipopolysaccharide group. In conclusion, CSF penetration of linezolid is not impacted by blood\u2013brain barrier disruption, unlike tedizolid, whose penetration ratio increased.\n                  <\/jats:p>","DOI":"10.1111\/cts.70100","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T02:18:03Z","timestamp":1737425883000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood\u2013brain barrier disruption"],"prefix":"10.1111","volume":"18","author":[{"given":"Marin","family":"Lahouati","sequence":"first","affiliation":[{"name":"Service de Pharmacie Clinique CHU de Bordeaux, H\u00f4pital Pellegrin  Bordeaux France"},{"name":"INSERM U1034, Biologie des Maladies Cardiovasculaires Universit\u00e9 de Bordeaux  Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Oudart","sequence":"additional","affiliation":[{"name":"Service de Pharmacie Clinique CHU de Bordeaux, H\u00f4pital Pellegrin  Bordeaux France"},{"name":"INSERM U1034, Biologie des Maladies Cardiovasculaires Universit\u00e9 de Bordeaux  Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Alzieu","sequence":"additional","affiliation":[{"name":"INSERM U1034, Biologie des Maladies Cardiovasculaires Universit\u00e9 de Bordeaux  Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Chapouly","sequence":"additional","affiliation":[{"name":"INSERM U1034, Biologie des Maladies Cardiovasculaires Universit\u00e9 de Bordeaux  Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Petitcollin","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmaco\u2010Toxicologie Biologique et M\u00e9dico\u2010L\u00e9gale CH Tarbes\u2010Lourdes  Tarbes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-196X","authenticated-orcid":false,"given":"Fabien","family":"Xuereb","sequence":"additional","affiliation":[{"name":"Service de Pharmacie Clinique CHU de Bordeaux, H\u00f4pital Pellegrin  Bordeaux France"},{"name":"INSERM U1034, Biologie des Maladies Cardiovasculaires Universit\u00e9 de Bordeaux  Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00007-10"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.07.030"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000418"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00757-x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw861"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg249"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2010.22.1.17"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.07.001"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv302"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab351"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/idr13030076"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.104420"},{"key":"e_1_2_10_14_1","unstructured":"European Medicines Agency.Guideline on bioanalytical method validation.2011. Accessed September 10 2024.www.ema.europa.eu\/contact"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250210158249"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.056697"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081729"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","unstructured":"O'brownNM PfauSJ GuC.Bridging barriers: a comparative look at the blood\u2010brain barrier across organisms.2018. doi:10.1101\/gad.309823","DOI":"10.1101\/gad.309823.117"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.768108"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2018.09.006"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872312813666190311125652"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0110-8"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03423-14"},{"key":"e_1_2_10_24_1","unstructured":"The European Committee on Antimicrobial Susceptibility Testing.Breakpoint tables EUCAST v14.0. Accessed May 6 2024.www.eucast.org"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.2011.164.issue-4"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0505-y"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:39:37Z","timestamp":1737689977000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/cts.70100"],"URL":"https:\/\/doi.org\/10.1111\/cts.70100","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70100"}}